Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-03-11
2008-03-11
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S469000, C548S483000, C548S490000
Reexamination Certificate
active
07342038
ABSTRACT:
The present invention provides substituted 3,3-diphenyl indole compounds, as well as analogues thereof, which are specific potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.
REFERENCES:
patent: 3546165 (1970-12-01), Morgan
patent: 4006023 (1977-02-01), McLaughlin et al.
patent: 4806685 (1989-02-01), Abraham et al.
patent: 4988785 (1991-01-01), Paul et al.
patent: 5273992 (1993-12-01), Brugnara et al.
patent: 5358959 (1994-10-01), Halperin et al.
patent: 5430062 (1995-07-01), Cushman et al.
patent: 5512563 (1996-04-01), Albright et al.
patent: 6800658 (2004-10-01), Brugnara et al.
patent: 2002/0128256 (2002-09-01), Brugnara et al.
patent: 3706427 (1988-09-01), None
patent: 10004654 (2001-08-01), None
patent: 0 323 740 (1989-07-01), None
patent: 483632 (1992-05-01), None
patent: 0 583 665 (1994-02-01), None
patent: 0 636 608 (1995-02-01), None
patent: 05 050771 (1993-03-01), None
patent: 05 58894 (1993-03-01), None
patent: WO 89/02741 (1989-04-01), None
patent: WO 89/08096 (1989-09-01), None
patent: WO 95/26720 (1995-10-01), None
patent: WO 96/08240 (1996-03-01), None
patent: WO 96/08242 (1996-03-01), None
patent: WO 96/36631 (1996-11-01), None
patent: WO 99/26624 (1999-06-01), None
patent: WO 02/32465 (2002-04-01), None
Matevosyan et al., CAPLUS Abstract 55:18704f-i, 1961.
Samoilova et al., CAPLUS Abstract 93:7272, 1980.
Varga et al., CAPLUS Abstract 117:277 (1992).
Kawada et al., CAPLUS Abstract 124:216109, 1996.
Aldrich Catalog, 1994-1995: Compounds 13, 484-8; T8,380-1; 10,130-3; D21,320-9; 32,543-0; 35,890-8; T8,160-4; 25,657-9; T8,470-0; T8,417-7; T8,360-7; S36,533-5; S50,949-3; 37,411-3; 37,152-1; 30,151-5; 27,520-4; 34,182-7; 35,889-4; S84,240-0; S79,226-8; 27,519-0; S64,640; S81,477-6; 36,005-8; S70,627-2; S34,966-6; S87,739-5; 11,500-2; S83,881-0; S58,110-0; 21,560-0; S91,408-8; S60,147-0; S83,571-4; S82,654-5; S8,388-2; S94,371-1; S87,649-6; S83,719-9; S83,042-9; S82,162-4; S81,468-7; S82,290-6; S79,387.
Ando, W., et al., “A Novel Reduction of α-Aryl Alkanols by Diiododimethylsilane,”Tetrahedron Letters, 51:4941-4942 (1979).
Barili et al., Chem. Abstract, 107:58774, 1987.
Barton, D. H. R., et al., “Pentavalent Organobismuth Reagents. Part 3. Phenylation of Enols and of Enolate and Other Anions,”J. Chem. Soc. Perkin Trans., 1:2667-2675 (1985).
Barton, D. H. R., et al., “Pentavalent Organobismuth Reagents. Part 3. Phenylation of Enols and of Enolate and Other Anions,”General Org. Chem., 105:531, col. 2, Abstract No. 208158b (1986).
Bartroli, J., et al., “Synthesis and Antifungal Activity of a Series of Difluorotritylimidazoles,”Arzneim.-Forsch./Drug Res., 42[I](6):832-835 (1992).
Benjamin, L. J., et al., “A Collaborative, Double-Blind Randomized Study of Cetiedil Citrate in Sickle Cell Crisis,”Blood, 67(5):1442-1447 (1986).
Benzaquen, L. R., et al., “Clotrimazole Inhibits Cell Proliferation in vitro and in vivo,”Nature Medicine, 1(6):534-540 (1995).
Bergman, J., et al., “Synthesis and Studies of Tris-Indolobenzenes and Related Compounds,”Tetrahedron, 36:1445-1450 (1980).
Bergman, J., et al., “Synthesis and Studies of Tris-Indolobenzenes and Related Compounds,”Chemical Abstracts, 94:368, col. 1, Abstract No. 3948s (1981).
Berkowitz, L. R., et al., “An Analysis of the Mechanism by Which Cetiedil Inhibits the Gardos Phenomenon,”American Journal of Hematology, 17:217-223 (1984).
Beutler, E., et al., “The Removal of Leukocytes and Platelets from Whole Blood,”J. Lab. Clin Med., 88(2):328-333 (1976).
Bontems, F., et al., “Analysis of Side-Chain Organization on a Refined Model of Charybdotoxin: Structural and Functional Implications,”Biochemistry, 31:7756-7764 (1992).
Brugnara, C., et al., “Oral Administration of Clotrimazole and Blockade of Human Erythrocyte Ca++-Activated K+ Channel: The Imidazole Ring is Not Required for Inhibitory Activity,” J. Pharmacology and Experimental Therapeutics, vol. 273, No. 1, pp. 266□272 (1995).
Brugnara, C., et al., “Ca2+-Activated K+Transport in Erythrocytes,”Journal of Biological Chemistry, 268(12):8760-8768 (1993).
Brugnara, C., et al., “Inhibition of Ca2+-Dependent K+Transport and Cell Dehydration in Sickle Erythrocytes by Clotrimazole and Other Imadazole Derivatives,”J. Clin. Invest., 92:520-526 (1993).
Brugnara, C., et al., “Inhibition of Gardos Channel and Red Cell Dehydration by Oral Administration of Clotrimazole in Sickle Cell Disease,”Blood, 220a:865 (1994).
Brugnara, C., et al., “Inhibition of Gardos Channel and Red Cell Dehydration by Oral Administration of Clotrimazole in Sickle Cell Disease,”The 20thAnnual Meeting of the National Sickle Cell Program, p. 138 (1995).
Brugnara, C., et al., “Erythrocyte Gardos Channel and Sickle Cell Disease: Pathophysiology and Clinical Significance,”Advanced Course and International Symposium on “Membrane Transporters and Channels” Program and Abstracts, Lecture 34 (1995).
Brugnara, C., et al., “Therapy with Oral Clotrimazole Induces Inhibition of the Gardos Channel and Reduction of Erythrocyte Dehydration in Patients with Sickle Cell Disease,”J. Clin. Invest., 97(5):1227-1234 (1996).
Burgess, M.A., et al., “Clotrimazole (Bay b 5097): In Vitro and Clinical Pharmacological Studies,”Antimicrobial Agents and Chemotherapy, 2(6):423-426 (1972).
Byers, H.R., et al., “Organ-Specific Metastases in Immunodeficient Mice Injected with Human Melanoma Cells: a Quantative Pathological Analysis,”Melanoma Research, 3:247-253 (1993).
Carter, A. J., et al., “Morphologic Characteristics of Lesion Formation and Time Course of Smooth Muscle Cell Proliferation in a Porcine Proliferative Restenosis Model,”JACC, 24(5):1398-1405 (1994).
Charache, S., et al., “Failure of Desmopressin to Lower Serum Sodium or Prevent Crisis in Patients with Sickle Cell Anemia,”Blood, 58(5):892-896 (1981).
Charache, S., et al., “Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia,”The New England Journal of Medicine, 332(20):1317-1322 (1995).
Clark, M. R., et al., “Hydration of Sickle Cells Using the Sodium Ionophore Monensin,”J. Clin. Invest., 70:1074-1080 (1982).
Chun, Moon Woo et al. “Reactivity of 3-Haloindolenines”, Chemical Abstracts, vol. 96, No. 17, Apr. 26, 1982, pp. 735.
Conte, L., et al., “Percutaneous Absorption and Skin Distribution of [14C]Flutrimazole in Mini-pigs,”Arzneim.-Forsch./Drug Res., 42[I](6):847-853 (1992).
Conte, L., et al., “Pharmacokinetic Study of [14C]Flutrimazole after Oral and Intravenous Administration in Dogs,”Arzneim.-Forsch./Drug Res., 42[I](6):854-858 (1992).
Corbett, T. H., “Preclinical Anticancer Activity of Cryptophycin-8,”Journal of Experimental Therapeutics&Oncology, 1:95-108 (1996).
Dakkouri et al, Chem. Abstract 126:305266, 1997.
Dakkouri et al., “Effect of Dielectric Constant and Ionic Strength on the Fading of N, N-Dimethylaminophenolphthalein in Alkaline Medium”, Chemical Abstract vol. 126, No. 23, Jun. 9, 1997, J. Chemical Education, 1997 74(5):556-559.
DeFranceschi, L., et al., “Treatment with Oral Clotrimazole Blocks Ca2+-Activated K+Transport and Reverses Erythrocyte Dehydration in Transgenic SAD Mice,”J. Clin. Invest., 93:1670-1676 (1994).
Grossi-Paoletti, E., et al., “Lipids in Brain Tumors,”J. Neurosurg., 34:454-455 (1971).
Guy, R. B., et al., “In Vitro and In Vivo Effect of Hypotonic Saline on the Sickling Phenomenon,”American Journal of Medical Sciences, 266(1):267-277 (1973).
Hanessian, S., et al., “Ethers and Anhydrosugars,”Methods Carbohydr. Chem., 7:63-67 (1
Bellott, Jr. Emile M.
Brugnara Carlo
Clifford John J.
Fluckiger Rudolf
Gao Ying-Duo
Children's Medical Center Corporation
Gardner Diane L.
Mastermind IP Law P.C.
NuChem Pharmaceuticals Inc.
President and Fellow of Harvard College
LandOfFree
Substituted diphenyl indanone, indane and indole compounds... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted diphenyl indanone, indane and indole compounds..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted diphenyl indanone, indane and indole compounds... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2792531